<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of Raynaud phenomenon: Initial management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of Raynaud phenomenon: Initial management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of Raynaud phenomenon: Initial management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fredrick M Wigley, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Raynaud phenomenon (RP) is an exaggerated vascular response to cold temperature or to emotional stress, which is manifested clinically by sharply demarcated color changes of the distal skin of the digits as well as toes, nose, and earlobes. Initial treatment includes patient education and general measures taken by the patient to prevent and treat attacks. In severe cases, treatment may include pharmacologic interventions and/or sympathetic blockade to prevent and treat digital ischemia.</p><p>The initial treatment of patients with uncomplicated RP is reviewed here. The treatment of patients who are refractory to initial therapy or with severe attacks or digital ischemic lesions is discussed separately (see  <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">"Treatment of Raynaud phenomenon: Refractory or progressive ischemia"</a>). The pathogenesis, clinical manifestations, and diagnosis of RP can also be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">"Treatment of Raynaud phenomenon: Refractory or progressive ischemia"</a> and  <a class="medical medical_review" href="/z/d/html/7553.html" rel="external">"Pathogenesis and pathophysiology of Raynaud phenomenon"</a> and  <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon"</a>.)</p><p class="headingAnchor" id="H1644624"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H3793766796"><span class="h2">Goals of therapy</span><span class="headingEndMark"> — </span>The goals of therapy are to improve quality of life and to prevent tissue loss (ie, ulceration, gangrene). At least a moderate reduction in the intensity of attacks and the prevention of tissue loss are achievable in most patients. However, abolishing cold sensitivity and eliminating all Raynaud events is not likely with available treatment options, particularly in patients with secondary Raynaud phenomenon (RP), due to the complexity and sensitivity of the regulation of thermoregulatory vessels in the skin. (See  <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Primary versus secondary Raynaud phenomenon'</a> and  <a class="medical medical_review" href="/z/d/html/7553.html" rel="external">"Pathogenesis and pathophysiology of Raynaud phenomenon"</a>.)</p><p class="headingAnchor" id="H743371205"><span class="h2">Patient education and self-management</span><span class="headingEndMark"> — </span>All patients should be educated about the potential causes of a Raynaud attack as well as the nonpharmacologic measures to help prevent and terminate an episode. These nonpharmacologic measures include avoidance of provoking factors such as cold temperature and vasoconstricting drugs, smoking cessation (when applicable), and other measures discussed further below. (See <a class="local">'Nonpharmacologic measures'</a> below.)</p><p>It is also important to explain to patients that the response to treatment can vary depending upon the presence or absence of an underlying disease; this is particularly important in patients with secondary RP, such as patients with systemic sclerosis (SSc, scleroderma), as such patients can have a structural component to their vascular disease in addition to the vasospastic component seen in all patients with RP. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Digital vasculopathy'</a>.)</p><p class="headingAnchor" id="H1151338375"><span class="h2">Measures of disease severity and impact</span><span class="headingEndMark"> — </span>It is challenging to fully appreciate the impact of RP due to the variability of the events and the lack of objective tools to define disease severity during real-life activities. The most common measures use patient-reported outcomes (eg, frequency and duration of attacks, degree of pain or sensory symptoms, perception of the intensity of color changes). A clinician’s global assessment has been used, but it is highly influenced by the patient-reported experience.</p><p>Two examples of outcome measures for Raynaud phenomenon include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Raynaud Condition Score</strong> – The Raynaud Condition Score (RCS) is a validated outcome measure that assesses the level of difficultly due to RP and captures other aspects of the patient’s experience [<a href="#rid1">1</a>]. The RCS asks the patient to consider the impact of the condition on their life, taking into account the frequency of attacks, the duration of attacks, the disability it is causing, and the effect on daily quality of life [<a href="#rid1">1,2</a>]. The RCS uses a visual scale (VAS) of 0 to 100; a change of approximately 15 is the minimum change considered clinically important [<a href="#rid3">3</a>]. It has been used in clinical trials as a semiquantitative tool to assess outcome.</p><p></p><p class="bulletIndent1">However, there has been concern that the RCS does not capture the complexity of patient perceptions. A survey found that RCS diary entries could be influenced by factors including seasonal variation in weather, efforts made by patients to avoid or ameliorate attacks of RP, habituation to RP symptoms, and patient coping strategies [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">A composite score has been proposed for use in clinical trials, which includes the RCS, frequency and duration of attacks, attack symptoms, and patient and physician VAS scores of global assessments of the RP [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of Systemic sclerosis-associated RAynaud's Phenomenon questionnaire</strong> – A novel approach has been developed using a patient-reported outcome measure to assess RP in patients with SSc, called the Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire [<a href="#rid6">6,7</a>]. This instrument was developed using patient interviews to capture the impact and severity of RP based on the experience of patients with SSc-related RP.</p><p></p><p>Measures such as the RCS and other patient-reported outcomes are tools typically used for assessment in clinical trials. Most clinical trials have a paper or electronic record of the number of daily attacks and of the duration of typical attacks. These data are then averaged over some defined period, usually weekly.</p><p>A number of laboratory-based measures (eg, laser Doppler, thermography, cold challenges) have been used, but none has become a standard measure for clinical trials or daily patient care because they do not capture the influence of shifting temperature, social interactions, and patient activities that occur outside a controlled laboratory setting. Ambulatory monitoring of skin temperature has been proposed as a potential outcome measure but has not been studied.</p><p class="headingAnchor" id="H188847410"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>Avoiding cold temperatures, the major trigger for Raynaud phenomenon (RP), is the most effective therapy available.</p><p>Most patients presenting with RP will respond to the typical measures described below with or without the addition of pharmacologic therapy  (<a class="graphic graphic_algorithm graphicRef126070" href="/z/d/graphic/126070.html" rel="external">algorithm 1</a>). A subset of patients, particularly those with secondary RP, can have severe digital ischemia requiring more advanced treatments or intervention. In addition, it is important to distinguish patients with acute hand ischemia due to etiologies that might mimic RP since some conditions may actually be worsened by the administration of pharmacologic agents typically useful for RP (eg, calcium channel blockers [CCBs]) [<a href="#rid8">8</a>]. This may occur if a systemic vasodilator reduces perfusion to digits that have fixed obstructive vascular disease. The treatment of severe RP characterized by refractory or progressive digital ischemia (ie, threatening digit loss) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/118660.html" rel="external">"Overview of upper extremity ischemia"</a> and  <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">"Treatment of Raynaud phenomenon: Refractory or progressive ischemia"</a>.)</p><p>The initial treatment of RP in most patients includes patient education and lifestyle modifications to maintain body warmth and avoid other triggers for RP. Pharmacotherapy is initiated if nonpharmacologic therapy is inadequate, with dihydropyridine CCBs being the preferred first-line agents. However, for patients who have contraindications to or do not tolerate CCBs, monotherapy with a phosphodiesterase type 5 (PDE5) inhibitor, a topical nitrate, an angiotensin receptor blocker, or a serotonin reuptake inhibitor are alternative options.</p><p class="headingAnchor" id="H197221250"><span class="h2">Nonpharmacologic measures</span><span class="headingEndMark"> — </span>We counsel all patients with RP to undertake a series of nonpharmacologic measures to help prevent attacks or reduce their severity, even in the summer months when RP may be less intense [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H321018500"><span class="h3">General measures</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of cold exposure</strong> – Avoidance of cold exposure and sudden temperature changes (when possible) is a key component of the management of RP. Patients should be made aware of circumstances that can trigger an attack such as putting one's hand in a refrigerator or freezer, holding an ice-cold drink, and entering an air conditioned environment such as the frozen food section of the supermarket or swimming in cold water. Modest seasonal changes such as cool rainy days can aggravate RP.</p><p></p><p class="bulletIndent1">There are no randomized trials that have investigated the effect of cold avoidance on symptoms of RP. This approach of avoiding a known trigger is based on our understanding of the mechanism of the disease along with common sense and anecdotal reports that taking measures to reduce cold exposure will limit the number of attacks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Strategies to maintain whole body and digital warmth</strong> – It is important to understand that one must keep the whole body warm and not just the hands and feet. We therefore advise that patients with RP use strategies that not only keep the digits warm (eg, hand warmers, warm socks), but also the whole body. Strategies to maintain body warmth include dressing warmly with thermal underwear, layered clothing, and a hat when going outside and arranging to have appropriate heating in both the home and working environment. This also includes measures to avoid whole body cold exposure such as not sitting still in cold breezes from air conditioning and avoiding situations that involve rapid changes from a warm to cold ambient temperature. Keeping the digits of the hands and feet warm with winter gloves, chemical hand warmers, and heavy wool socks may also help. Heating up clothing in a dryer and putting them on while they are still warm before entering a cold environment is suggested as helpful.</p><p></p><p class="bulletIndent1">Limited evidence from two small observational studies of patients with systemic sclerosis (SSc, scleroderma) have suggested that warming the hands can reduce cold-induced symptoms [<a href="#rid10">10,11</a>]. A number of different types of gloves have been proposed for patients with RP to reduce the likelihood of attacks, including battery-heated gloves and gloves knotted with silver thread. The only randomized trial to evaluate specialized gloves, specifically ceramic-impregnated gloves, had significant methodologic issues, making it difficult to interpret the findings [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">Patients should also be taught methods to help terminate an attack of RP. These include placing the hands under warm water or in a warm place (such as the axilla) or rotating arms in a whirling or windmill pattern. A maneuver similar to throwing a Frisbee can also be used [<a href="#rid13">13</a>]. Rubbing the hands together can also help warm the hands and restore blood flow. A typical attack lasts approximately 15 to 20 minutes after rewarming.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other general measures:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoidance of repeated trauma to the fingertips by all patients with RP and avoidance of vibrating tools by patients with vibration-induced RP [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We do not routinely counsel patients with RP to stop consuming caffeine-containing drinks, although some experts have recommended doing so. The impact of caffeine on RP has not been defined, and its xanthine-related properties may result in systemic vasodilation [<a href="#rid15">15,16</a>]. Coffee consumption has been associated with vasoconstrictive effects, which transiently increase blood pressure (BP). However, coffee contains many biologically active compounds in addition to caffeine and overall may have vascular benefit [<a href="#rid17">17</a>]. Thus, the decision to stop caffeine-containing drinks should be based on the patient's experience.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with RP undergoing surgery, the risk of attacks from increased cold exposure in the operating room can be reduced by keeping patients warm. The choice of medications in patients undergoing an attack in this setting should be individualized based upon the specific clinical circumstances.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Control or limitation of emotional stress because the thermoregulatory vessels are constricted by increased sympathetic tone. Stress plus cold exposure is an especially potent trigger for RP [<a href="#rid18">18</a>].The exact impact of stress and anxiety has been challenging to define due to the lack of studies accounting for the influence of ambient temperature and differences between laboratory-based studies and real life experiences. In a laboratory study of patients with primary RP, finger temperature decreased when subjects viewed a cold-related stress situation [<a href="#rid19">19</a>]. An ambulatory study in over 300 patients with primary RP found a relationship between the trait of anxiety and severity of RP [<a href="#rid20">20</a>]. Most interventions have focused on managing stress situations rather than treating any defined mental health condition. To date, clinical trial evidence does not support behavioral therapy (eg, biofeedback, relaxation therapy) in the treatment of RP. A systematic review of behavioral interventions concluded that no adequately designed or large enough trials exist to clearly support these therapies for RP management [<a href="#rid21">21</a>]. The management of anxiety and stress in the treatment of RP is primarily based on clinical and patient-related experiences, and attention to depression and anxiety disorders should be provided. (See <a class="local">'Therapies lacking efficacy or of uncertain benefit'</a> below.)</p><p></p><p class="headingAnchor" id="H1126971630"><span class="h3">Avoidance of vasoconstricting drugs</span><span class="headingEndMark"> — </span>Patients should be advised to avoid medications known to worsen vasospasm, when possible. There are almost no formal studies that have evaluated the effects of various drugs on RP; however, since the therapeutic mechanism of some drugs is known to cause vasospasm, we advise that these medications be avoided. Several classes of drugs known to be associated with vasospasm include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Over-the-counter nasal decongestants (eg, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>, <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">pseudoephedrine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Amphetamines, diet pills, and herbs with ephedra</p><p class="bulletIndent1"><span class="glyph">●</span>Agents used to treat attention deficit hyperactivity disorder (ADHD; <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> and <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">dextroamphetamine</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Some medications used for migraine headaches, including serotonin agonists (eg, <a class="drug drug_general" data-topicid="9968" href="/z/d/drug information/9968.html" rel="external">sumatriptan</a>), <a class="drug drug_general" data-topicid="9416" href="/z/d/drug information/9416.html" rel="external">ergotamine</a>, and calcitonin gene related peptide (CGRP) receptor antagonists</p><p></p><p>The only study that investigated the relationship between a medication and RP was a small case-control study including 64 pediatric rheumatology patents, half of whom had RP [<a href="#rid22">22</a>]. The presence of RP was associated with past or current use of stimulants for ADHD (<a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> and <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">dextroamphetamine</a>).</p><p>An aggravating role of estrogen use is suggested by the finding that postmenopausal women using unopposed estrogens have a higher prevalence of RP [<a href="#rid23">23</a>]. However, while the exact impact of estrogens is not fully defined, most experts avoid estrogen replacement in patients with severe RP.</p><p>There have been case reports of RP occurring after either the small molecule CGRP receptor antagonists or monoclonal antibody antagonists [<a href="#rid24">24,25</a>]. Until additional data are available, CGRP-targeting drugs should be used with caution in patients with RP [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H4172582346"><span class="h3">Smoking cessation</span><span class="headingEndMark"> — </span>The vascular effects of smoking do not appear to be any different in patients with RP [<a href="#rid28">28</a>]. Thus, avoidance of smoking is advised since smokers are sensitized to the vasoconstrictive properties of cigarettes. Avoiding secondhand smoke and electronic cigarettes is also prudent. (See  <a class="medical medical_review" href="/z/d/html/16706.html" rel="external">"Benefits and consequences of smoking cessation"</a> and  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults"</a>.).</p><p>The detrimental effects of smoking are multifactorial, with mechanisms that include vasoconstriction and alterations in wound healing [<a href="#rid28">28,29</a>]. A large study including over 600 patients with SSc found that smoking was associated with substantially worse RP symptoms and that symptom severity decreased after smoking cessation [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H861559162"><span class="h2">Pharmacologic measures</span></p><p class="headingAnchor" id="H1361709191"><span class="h3">Initial pharmacologic therapy</span><span class="headingEndMark"> — </span>The decision to either initiate or assess treatment for RP is ultimately going to be based on clinician-patient discussions considering reported symptom severity, impact on their quality of life, drug tolerability, and the perceived effectiveness of existing and/or planned interventions. (See <a class="local">'Measures of disease severity and impact'</a> above.)</p><p>A review of therapy for primary RP noted that apart from calcium channel blockers (CCBs), which are considered to be the drugs of choice, evidence of the effects of alternative pharmacologic treatments is limited by studies of small sample sizes, limited data, and variability in outcome reporting yielding evidence of very low to moderate certainty [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H188847417"><span class="h4">Calcium channel blocker</span><span class="headingEndMark"> — </span>In patients with uncomplicated RP who have not responded adequately to nonpharmacologic measures, we suggest the use of long-acting dihydropyridine CCBs. There are no clear data to support the use of one dihydropyridine CCB over another. <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">Amlodipine</a> is preferred by the author. Others may prefer <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> because it is the CCB that has been the most studied for RP. There are no studies that have directly compared CCBs for RP. Generally, long- rather than short-acting formulations of CCBs should be used given the ease of administration and better safety profile of longer-acting CCBs.</p><p>Effective doses of <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> range from 5 to 20 mg/day, and effective doses of long-acting <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> range from 30 to 120 mg/day. We start with the lowest dose and gradually increase, depending upon the response. The duration of a drug trial at a given dose should be determined by the period of observation needed to assess whether there has been a clinically meaningful reduction in the frequency and severity of acute attacks, and by the degree to which the drug is tolerated. In most nonurgent situations, the dose is adjusted every four weeks and no more frequently than every 7 to 10 days. Systemic BP measurements should be followed serially during the titration of the CCB. When possible, we advise patients to obtain a BP cuff to monitor their BP daily until dosing is stable and then weekly thereafter, as well as when symptoms of hypotension occur. The major side effects associated with the CCBs include hypotension, headache, dizziness, flushing, tachycardia, and peripheral edema [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers"</a>.)</p><p>Individual responses to the CCBs may vary. If <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> or <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> is ineffective at the highest tolerated dose, then another dihydropyridine CCB may be substituted, such as <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">nicardipine</a>, <a class="drug drug_general" data-topicid="8438" href="/z/d/drug information/8438.html" rel="external">felodipine</a>, lacidipine, <a class="drug drug_general" data-topicid="9703" href="/z/d/drug information/9703.html" rel="external">nisoldipine</a>, <a class="drug drug_general" data-topicid="9702" href="/z/d/drug information/9702.html" rel="external">nimodipine</a>, and <a class="drug drug_general" data-topicid="8585" href="/z/d/drug information/8585.html" rel="external">isradipine</a> [<a href="#rid32">32-41</a>]. The nondihydropyridine CCBs are generally avoided because they have not been shown to be consistently effective [<a href="#rid42">42-44</a>].</p><p>The duration of benefit from drug intervention in RP has not been formally studied. Most reported clinical trials are short term, typically four to six weeks in duration. In our experience, there is sustained benefit from treatment with a CCB. This impression is based upon the consistent occurrence of relapses of severe Raynaud events if a CCB is discontinued. However, there are little objective data to define the duration of benefit of single or combination drug therapy.</p><p>The efficacy of various CCBs compared with placebo in reducing the frequency and severity of Raynaud attacks has been demonstrated in randomized trials and meta-analyses [<a href="#rid45">45-50</a>]. However, the overall effects of CCBs on RP attacks generally appear to be small. It is important to note that clinical trials differ in the various measures to define whether or not there was a response to therapy, making it difficult to compare studies. The most commonly reported outcome is self-recorded frequency and severity of attacks and the Raynaud Condition Score (RCS). Duration of attacks and patient and physician global assessments are also used but have poor reliability. Placebo response rates are high and laboratory measures (thermography, laser Doppler flow) differ from subjective data collected in an ambulatory setting. Thus, much of the variability in findings is related to small sample sizes, mixed populations (with primary versus secondary RP), different outcome measures, and differences in the type and dose of CCB. (See <a class="local">'Measures of disease severity and impact'</a> above.)</p><p>A systematic review and meta-analysis that examined the effects of dihydropyridine CCBs on primary and secondary RP using data from 23 trials with 528 participants found that CCBs were superior to placebo in reducing the frequency of attacks [<a href="#rid50">50</a>]. CCBs reduced the average number of attacks per week by six (weighted mean difference [WMD] -6.13, 95% CI -6.60 to -5.67) compared with 13.7 attacks per week with placebo. When one of the studies with the largest reduction in frequency of attacks was excluded [<a href="#rid51">51</a>], CCBs reduced attack frequency by 2.93 per week (95% CI -3.44 to -2.43).</p><p>Another systematic review and meta-analysis of 58 trials including 3867 patients studied the safety and efficacy of various treatments for secondary RP [<a href="#rid52">52</a>]. The meta-analysis demonstrated that CCBs were superior to placebo for reducing the daily frequency of attacks, with a mean difference of -0.35 (95% CI -0.67 to -0.02), and for reducing severity of attacks, with a mean difference of -0.84 (-1.25 to -0.45) on a 10-point scale.</p><p>Although CCBs were also found to reduce attack severity, it is uncertain whether the reductions are clinically meaningful. Improvements in pain and disability also favored CCBs, but the effect estimates were likely underpowered to confirm definable impact.</p><p class="headingAnchor" id="H3430450248"><span class="h3">Unable to tolerate or receive preferred initial therapy</span><span class="headingEndMark"> — </span>Alternative therapies may be required in patients in whom CCBs are contraindicated or poorly tolerated (eg, patients with severe gastrointestinal dysmotility, severe pulmonary artery hypertension, significant cardiac disease with edema, and/or low BP). The decision to use one agent over another depends largely on the side effect profile and whether there are additional benefits for other comorbidities. As an example, a PDE5 inhibitor may be preferable to a CCB in a patient with RP secondary to SSc, particularly in a patient with concomitant pulmonary hypertension. (See  <a class="medical medical_review" href="/z/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis"</a>.) </p><p class="headingAnchor" id="H752092763"><span class="h4">Phosphodiesterase type 5 inhibitor</span><span class="headingEndMark"> — </span>We use a low-dose PDE5 inhibitor in patients with uncomplicated RP in whom CCBs are contraindicated or not tolerated. We typically start with <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> 20 mg once or twice daily and increase the dose to 20 mg three times daily if no benefit is achieved. The dose may be further increased to 40 mg three times daily in patients who do not respond and can tolerate the higher dosing. This dose is similar to that used in patients with pulmonary hypertension. Sildenafil is also available as 25 mg and may be titrated up to 50 mg twice or three times daily as tolerated in a similar manner to that of the 20 mg formulation. As with CCBs, we advise that patients obtain a BP cuff to monitor their BP serially while titrating the dose. (See  <a class="medical medical_review" href="/z/d/html/8256.html" rel="external">"Pulmonary arterial hypertension in systemic sclerosis (scleroderma): Treatment and prognosis", section on 'Phosphodiesterase type 5 inhibitors'</a>.)</p><p>A PDE inhibitor should not be used together with topical nitrates due to the increased risk of hypotension. Other adverse effects that may occur include peripheral edema, palpitations, tachycardia, hearing loss, and visual disturbances.</p><p>A meta-analysis of nine randomized trials including 411 patients with RP (most of whom had secondary RP with scleroderma) found with low-certainty evidence that treatment with PDE5 inhibitors (eg, <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a>, <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">tadalafil</a>, and <a class="drug drug_general" data-topicid="10172" href="/z/d/drug information/10172.html" rel="external">vardenafil</a>) resulted in three fewer attacks weekly and a reduction in the average duration of the attacks by five minutes [<a href="#rid53">53</a>]. The evidence did not provide comparisons of different PDE5 inhibitors. In another meta-analysis of six randomized trials including 244 patients with secondary RP, PDE inhibitors reduced the frequency of RP attacks by approximately 0.5/day compared with placebo, which is comparable to the reduction reported in another meta-analysis assessing the efficacy of CCBs in SSc-related RP (0.6/day) [<a href="#rid46">46,54</a>]. The RCS represents the level of difficulty experienced by the patient each day that is attributed to RP, and is assessed using a visual analog scale. Although the improvement in the RCS was statistically significant according to the meta-analysis [<a href="#rid54">54</a>], it was not considered to be a clinically meaningful difference [<a href="#rid3">3</a>].</p><p>Another systematic review reported that PDE5 inhibitors were more effective compared with placebo for reducing the frequency, duration, and severity of attacks, but the quality of evidence was low and the effect size was moderate [<a href="#rid52">52</a>]. Twelve trials of PDE5 inhibitors (mostly in patients with secondary RP) were included. The mean differences between PDE5 inhibitor and placebo (as measured on a 10-point scale) were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Daily frequency of attacks – Mean difference -0.36, 95% CI -0.69 to -0.04</p><p class="bulletIndent1"><span class="glyph">●</span>Severity – Mean difference -0.34, 95% CI -0.66 to -0.03</p><p class="bulletIndent1"><span class="glyph">●</span>Duration – Mean difference -3.42, 95% CI -6.62 to -0.29</p><p></p><p>A study using n-of-1 trials in 38 patients with RP did not demonstrate clinically relevant effects for on-demand <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">sildenafil</a> use before or during exposure to cold [<a href="#rid55">55</a>]. Although the analysis reported a high probability that sildenafil was superior to placebo, there was substantial heterogeneity among the patient responses, with a clinically relevant benefit in just a few patients. The strength of the n-of-1 study design is that it allows the estimation of therapeutic effect in each patient and permits correlation of individual outcomes and patient preference.</p><p>The benefits of PDE inhibitors for patients with recurrent digital ulcers and RP due to SSc is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">"Treatment of Raynaud phenomenon: Refractory or progressive ischemia", section on 'Phosphodiesterase type 5 inhibitors'</a>.)</p><p class="headingAnchor" id="H3244355517"><span class="h4">Topical nitrate</span><span class="headingEndMark"> — </span>In our experience, the topical nitrates are more useful for patients with a single or small number of severely affected digits and for short-term (days to weeks) use, compared with patients with more diffuse involvement and with the need for chronic use (months to years). In patients with low BP, dehydration, acute or chronic heart failure, pulmonary hypertension, or ongoing use of a PDE inhibitor, topical nitrates should be avoided. Topical nitrates should be avoided in patients in using PDE inhibitors due to the increased risk of hypotension.</p><p>Topical nitrate should be applied to a single more severely affected or ischemic digit for 6 to 12 hours. Starting at a low dose of 0.5 inch (or 1 to 2 cm) is recommended to define tolerance before increasing dose if no improvement. The dose of topical nitrate may vary depending upon the preparation and should be adjusted with close monitoring of tolerance and the clinical response. The <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">nitroglycerin</a> 2% ointment can be titrated as needed up to a full 2 inches (approximately 5 cm) every 4 to 6 hours with a 12-hour nitrate-free period each day. However, the higher dose is often not well tolerated, and patients stop usage. The dose may be divided between several digits, although absorption with most preparations results in systemic effects. Side effects include headache, flushing, lightheadedness, decreased BP, tachycardia, and aggravation of gastroesophageal reflux.</p><p>Several small observational studies and randomized trials of different topical nitrates suggest benefit in patients with RP [<a href="#rid56">56-61</a>]. One large randomized trial that used a novel gel formulation of a topical nitrate (MQX-503) versus placebo included 219 patients, 69 with primary RP and 150 with secondary RP [<a href="#rid58">58</a>]. The mean improvement in RCS (0 to 10 scale) was significantly greater in the MQX-503 group than in the placebo group (14.3 versus 1.3 percent). However, there was no statistically significant change in frequency or duration of attacks. Patients with primary RP experienced more benefit than those with secondary RP. A systematic review and meta-analysis of topical nitrates included seven randomized trials with 346 patients with either primary or secondary RP reported a treatment benefit (standardized mean difference 0.7, 95% CI 0.35-1.05), which was a pooled measure of clinical and blood flow outcomes [<a href="#rid61">61</a>]. Subgroup analyses showed a larger treatment effect for secondary compared with primary RP. Important limitations to the study include the use of multiple topical nitrate preparations and the integration of different outcome measurements.</p><p class="headingAnchor" id="H1135063315"><span class="h4">Angiotensin II receptor blocker</span><span class="headingEndMark"> — </span>Angiotensin II receptor blockers (ARBs) may be used for patients with uncomplicated RP who cannot tolerate CCBs or who may benefit from the use of an ARB for other indications (eg, hypertension, heart failure, proteinuric chronic kidney disease). There is limited evidence supporting the use of ARBs as being effective for RP. In a small 12-week trial in patients with primary and secondary (SSc-related) RP, patients receiving <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">losartan</a> (50 mg/day) experienced a greater reduction in the severity and frequency of attacks compared with <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> (40 mg/day) [<a href="#rid62">62</a>]. However, the trial was too small to analyze differences between groups to determine if losartan was superior to nifedipine. The evidence for the use of angiotensin-converting enzyme (ACE) inhibitors is much less favorable. (See <a class="local">'Therapies lacking efficacy or of uncertain benefit'</a> below.)</p><p class="headingAnchor" id="H2152014687"><span class="h4">Selective serotonin reuptake inhibitor</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">Fluoxetine</a> may be used in patients with uncomplicated RP who cannot tolerate CCBs or the systemic vasodilatory effects of some of the other alternative agents. Limited evidence from preliminary observations and only one small open-label crossover study suggest that fluoxetine may be of benefit for RP [<a href="#rid63">63,64</a>]. In a small study including 53 patients with primary or secondary RP, the use of fluoxetine (20 mg daily) or <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> (40 mg daily) for six weeks resulted in a reduction in attack frequency and severity of RP; the effect was only statistically significant for the fluoxetine group [<a href="#rid64">64</a>]. It is advised that patients start at a dose of 10 mg daily for approximately one week for tolerability before increasing to 20 mg daily. While not formally studied, a selective serotonin reuptake inhibitor may also be helpful to treat the patient with RP who have an anxiety disorder.</p><p class="headingAnchor" id="H3065427580"><span class="h2">Inadequate response to calcium channel blocker or alternative agent</span><span class="headingEndMark"> — </span>Prior to a trial of combination therapy of a CCB with another agent for patients who do not respond to initial therapy, we take the following measures:</p><p class="bulletIndent1"><span class="glyph">●</span>Review and reinforce the importance of continuing the general nonpharmacologic measures for prevention and treatment. Remember that lifestyle adjustments with cold avoidance is the best treatment for RP and it can improve with time, especially in patients with primary RP. (See <a class="local">'Nonpharmacologic measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Revisit the underlying cause for RP to readdress reversible causes or treatable aggravating or comorbid conditions. (See  <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Differential diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H749017312"><span class="h3">Combination of calcium channel blocker with another agent</span><span class="headingEndMark"> — </span>In patients who do not respond adequately to a CCB alone, we typically add or substitute either a PDE5 inhibitor or a topical nitrate. We would add <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> for patients who cannot tolerate the systemic vasodilatory effects of some of the other alternative agents. However, the magnitude of the benefit (and whether other selective serotonin uptake inhibitors are equally beneficial) requires further study.</p><p>There are no randomized trials that address the efficacy of combination therapy of a CCB plus another vasodilatory agent, and the rationale behind this approach is based on the benefits observed with the individual agents. The combination of PDE5 inhibitors and topical nitrates should be avoided due to the increased risk of hypotension. (See <a class="local">'Phosphodiesterase type 5 inhibitor'</a> above and <a class="local">'Topical nitrate'</a> above.)</p><p class="headingAnchor" id="H690797994"><span class="h2">Monitoring response to therapy</span></p><p class="headingAnchor" id="H1979726083"><span class="h3">Routine follow-up</span><span class="headingEndMark"> — </span>Patients should be evaluated periodically, ideally every three to six months, to identify the need for ongoing or additional treatments. Vasodilator therapy may improve RP events rapidly, but the long-term benefit has not been studied and is influenced by many factors including the underlying cause, ambient temperature, level of effective cold and stress avoidance. It is important to take into account the risk of the treatment, the clinical evidence for its effectiveness, and the need for continued therapy at the time of the evaluation, balancing the risks of therapy and the level of severity of the RP. The goal is not to eliminate every attack but to avoid ischemic complications and improve quality of life.</p><p>In clinical practice, a practical approach to assessing the response to therapy is to ask the patient questions similar to those used for the RCS. This includes asking the patient to consider the impact of the condition on their life, taking into account the frequency of attacks, the duration of attacks, the disability it is causing, and the effect on daily quality of life. A survey of subjects with RP reported that 56 percent responded that they could predict when an attack would occur, 64 percent reported they had poor control of attacks, and 78 percent made lifestyle changes in an attempt to avoid an RP event [<a href="#rid65">65</a>]. A second survey of patient-defined RP reported that patients rarely used the term “attack” but had a reduced quality of life and described RP as “debilitating,” “embarrassing,” or “horrible.” In a survey from Sweden, RP did not prevent patients from their work activity [<a href="#rid66">66</a>]. (See <a class="local">'Measures of disease severity and impact'</a> above.)</p><p>However, it is difficult to determine the full impact of a drug intervention in that the severity and frequency is influenced by many factors including seasonal temperature changes, lifestyle adjustments, and patient acclimation. In one survey, most subjects (78 percent) reported making at least one adjustment to their life due to RP, more so for secondary RP than primary RP (87 versus 71 percent) [<a href="#rid65">65</a>]. Another study found that attack frequency and duration was not prioritized by patients as factors that would lead them to consider treatment escalation [<a href="#rid67">67</a>]. They reported the inability to use their hands properly due to RP as the highest-ranked factor that might prompt change of treatment or initiation of drug therapy. (See <a class="local">'Measures of disease severity and impact'</a> above.)</p><p class="headingAnchor" id="H1427078252"><span class="h3">Refractory or progressive ischemia</span><span class="headingEndMark"> — </span>Patients with secondary RP associated with scleroderma experience clinical changes that persist between isolated RP events and have a major impact on quality of life due to pain, impaired hand function, the perception of body image and reliance on others [<a href="#rid68">68</a>]. The management of severe RP resistant to initial therapy or severe events with digital ulcers or ischemic lesions (ie, tissue loss) is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">"Treatment of Raynaud phenomenon: Refractory or progressive ischemia"</a>.)</p><p class="headingAnchor" id="H1623111338"><span class="h1">THERAPIES LACKING EFFICACY OR OF UNCERTAIN BENEFIT</span><span class="headingEndMark"> — </span>Other treatments have been proposed and have been subjected to limited study; sufficient evidence is lacking at present to support the routine use of any of the therapies discussed below in place of other interventions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavioral therapy</strong> – There are no robust trials showing benefit of behavioral therapy for reducing the number or severity of attacks in Raynaud phenomenon (RP). Some techniques that have been studied include biofeedback training, autogenic training, and classical conditioning. Most studies have used temperature biofeedback for RP, where finger temperature data are provided to patients to help them learn to relax by monitoring their internal states and changing temperature. However, the majority of biofeedback trials are generally low quality and have used small numbers of patients [<a href="#rid20">20,69-72</a>]. The best data come from a trial including 313 patients with primary RP that randomized patients to sustained-release <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a>, placebo, temperature biofeedback, and sham biofeedback and found that patients who received temperature biofeedback did not reduce RP attacks compared with sham biofeedback at one-year follow-up [<a href="#rid32">32</a>]. The study concluded that temperature biofeedback was not more effective than a sham procedure and was inferior to nifedipine treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complementary and alternative medicine</strong> – A literature review and meta-analysis of the efficacy of complementary and alternative medicine in the treatment of RP found that most studies were inconclusive and that there is a need for well-designed studies in this area of treatment for RP [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antioxidant agents – Antioxidant agents such as <a class="drug drug_general" data-topicid="96338" href="/z/d/drug information/96338.html" rel="external">zinc gluconate</a> (50 to 150 mg/day) have also been utilized based upon the rationale that they may reduce tissue damage that may occur during ischemia-reperfusion from superoxide production [<a href="#rid74">74-76</a>]. In one study, intravenous (IV) <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> reduced the frequency and severity of RP attacks compared with baseline and, in another uncontrolled study, reduced digital ulcers and severity of RP in systemic sclerosis (SSc, scleroderma) patients [<a href="#rid77">77,78</a>]. Probucol, a synthetic antioxidant, improved RP compared with a control group [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ginkgo biloba – Ginkgo biloba is an herbal medication that we do not use because the preponderance of evidence has not shown it to be beneficial [<a href="#rid80">80,81</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acupuncture – Acupuncture has been reported to improve primary RP, but there is not enough evidence to determine effectiveness [<a href="#rid82">82</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laser irradiation – Therapeutic gloves [<a href="#rid12">12</a>] and low-level laser therapy [<a href="#rid83">83,84</a>] are reported to improve RP, but the data are limited.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spinal cord stimulation – Spinal cord stimulation has been used for treatment in RP, but no controlled study is available [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Angiotensin-converting enzyme inhibitors</strong> – There is little evidence to suggest that angiotensin-converting enzyme (ACE) inhibitors are effective for RP. Despite an open-label study that suggested some benefit from use of <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a> in patients with primary (but not secondary) RP [<a href="#rid86">86</a>], a meta-analysis of treatment in primary RP combined data from three studies and reported a possible small increase in the frequency of attacks per week after treatment (captopril or <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">enalapril</a>) compared with placebo (mean difference 0.79, 95% CI 0.43-1.17 with low‐certainty evidence) [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">A subsequent randomized trial involving 210 patients with secondary RP also did not support the use of an ACE inhibitor for this indication [<a href="#rid87">87</a>]. The trial found no evidence of benefit for <a class="drug drug_general" data-topicid="9843" href="/z/d/drug information/9843.html" rel="external">quinapril</a>, an ACE inhibitor, in the incidence of digital ulcers or in the frequency or severity of attacks of RP [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">Prazosin</a> – Because of the lack of robust studies and the availability of alternative agents, we no longer use prazosin in the treatment of RP. In our experience, patients eventually become refractory to this agent after prolonged usage. Prazosin, an alpha-1-adrenergic receptor antagonist, was found to be beneficial in two small randomized trials [<a href="#rid88">88,89</a>]. In one study, a blinded crossover study of 14 patients with primary and secondary RP, nine patients reported fewer episodes of RP during the two-week study period [<a href="#rid88">88</a>]. Only one of five patients with SSc reported improvement with prazosin. A dose of 1 mg three times daily was reported to improve RP compared with placebo and was tolerated with fewer side effects compared with higher doses [<a href="#rid89">89,90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other medications</strong> – Several other medications that have been used for which there are limited data to define clinical utility include the sympatholytic drugs <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a> and reserpine (which has been given intra-arterially) [<a href="#rid91">91-98</a>]. However, none of these agents is a specific inhibitor of the alpha-2C-adrenergic receptor that is thought to be the major pathway through which cold-induced digital artery vasoconstriction is triggered. A laboratory-based study using a specific alpha-2C adrenergic receptor antagonist demonstrated improvement in cold-induced skin temperature, suggesting that similar agents may be helpful in the treatment of RP, but a specific alpha-2C agent is not available [<a href="#rid99">99</a>]. <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> has been found to provide some benefit in a study of 11 patients with primary RP (including increased blood flow) [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent1">There is in vitro evidence that estrogen increases smooth muscle expression of alpha2C-adrenoceptors and thus can enhance cold-induced constriction of cutaneous arteries [<a href="#rid101">101</a>]. Epidemiological studies report that unopposed estrogen therapy is associated with RP in postmenopausal women [<a href="#rid23">23</a>] However, the influence of estrogens on the vasculature is complex with evidence of mediating vasodilation in coronary and brachial vessels [<a href="#rid102">102,103</a>]. Given the lack of adequate evidence, hormonal therapy for RP is not recommended.</p><p></p><p class="bulletIndent1">A number of other agents have been studied but failed to show adequate benefit, had an inadequate study design, or demonstrated unacceptable levels of safety compared with other available medications. These agents include ketanserin, L-arginine, calcitonin gene-related peptide, and a thromboxane A2 inhibitor [<a href="#rid104">104-107</a>]. Other such agents include direct vasodilators, such as <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a>; <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">hydralazine</a>; <a class="drug drug_general" data-topicid="9739" href="/z/d/drug information/9739.html" rel="external">papaverine</a>; <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a>; <a class="drug drug_general" data-topicid="9695" href="/z/d/drug information/9695.html" rel="external">niacin</a>; and topical agents, including nitric-oxide (via a generating system), hexyl nicotinate, and ethyl nicotinate [<a href="#rid57">57,108</a>]. Sarpogrelate hydrochloride, a 5-hydroxytryptamine 2A serotonin receptor (5-HT2A) inhibitor available in Japan, has been reported to improve RP and to reduce digital ulcers [<a href="#rid109">109-111</a>]. A review of Chinese herbal medicine for the treatment of primary RP suggested they may have a positive effect [<a href="#rid112">112</a>]. However, these findings are inconclusive given weak methodology.</p><p></p><p class="headingAnchor" id="H3060717"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Primary Raynaud phenomenon (RP) is a benign condition; it is often transient in nature and may improve or disappear with time in one-third or more of patients over 7 to 14 years of follow-up [<a href="#rid113">113,114</a>]. However, many patients with primary RP report that it has significant impact on their quality of life due to cold and uncomfortable fingers and hands. This is particularly true in individuals who have occupations that do not allow effective cold avoidance. An international survey of the self-reported impact of RP found over 25 percent of patients included reduced quality of life, describing feelings of embarrassment and alterations in physical and social function [<a href="#rid115">115</a>]. By comparison, patients with secondary RP are more likely to have severe attacks and sustained or progressive disease. Patients with associated systemic rheumatic disease, particularly systemic sclerosis (SSc, scleroderma), may develop persistent digital ischemia requiring aggressive intervention, which is not always effective. It is notable that a survey of 443 patients with self-reported primary or secondary RP from 15 countries found that 64 percent reported a poor or very poor current ability to prevent/control RP attacks despite lifestyle changes and prescribed medications [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon"</a>.)</p><p>Spontaneous remission of primary RP may occur. This was illustrated in a prospective study that surveyed a middle-aged White American population over a seven-year period [<a href="#rid114">114</a>]. For those who had, or who developed, primary RP during that time frame, remissions occurred in 64 percent of both females and males. However, some symptoms suggestive of RP continued in about 20 percent of the cases that were classified as in "remission."</p><p>By comparison, remission is uncommon in patients with secondary RP.</p><p class="headingAnchor" id="H2588794159"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118057.html" rel="external">"Society guideline links: Raynaud phenomenon"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15533.html" rel="external">"Patient education: Raynaud phenomenon (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3438.html" rel="external">"Patient education: Raynaud phenomenon (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – The goals of therapy of Raynaud phenomenon (RP) are to improve quality of life and to prevent ischemic tissue injury. All patients should also be educated about the potential causes of a Raynaud attack as well as the nonpharmacologic measures to help prevent and terminate an episode. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong> – The initial treatment approach varies depending on the severity of Raynaud events and whether or not the patient has experienced complications (eg, digital ulcers, critical ischemia). For patients who have uncomplicated RP (ie, the absence of irreversible ischemic tissue loss), nonpharmacologic therapies alone or in combination with a pharmacologic agent are usually adequate to provide control of symptoms  (<a class="graphic graphic_algorithm graphicRef126070" href="/z/d/graphic/126070.html" rel="external">algorithm 1</a>). Nonpharmacologic interventions alone are typically insufficient to control RP events in patients who develop severe disease resulting in irreversible ischemic lesions. Such patients typically require pharmacologic intervention. (See <a class="local">'Initial management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General measures</strong> – We counsel all patients with uncomplicated RP to undertake a series of nonpharmacologic measures to help prevent attacks or reduce their severity. These measures include avoiding cold exposure, implementing strategies to maintain body and digital warmth, avoiding vasoconstricting drugs, and smoking cessation. Management of emotional stress is also advised. (See <a class="local">'Nonpharmacologic measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial pharmacologic therapy</strong> – For patients with uncomplicated RP who have not responded adequately to nonpharmacologic measures, we suggest the use of long-acting dihydropyridine calcium channel blockers (CCBs) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). There is good evidence of the efficacy of CCBs compared with placebo, and there is more experience with their use compared with alternative oral agents. We start with the lowest dose and gradually increase as needed depending on the response. (See <a class="local">'Calcium channel blocker'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unable to tolerate or receive preferred initial therapy</strong> – For patients with uncomplicated RP in whom CCBs cannot be administered, alternative options include phosphodiesterase type 5 (PDE5) inhibitors, topical nitrates, <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">losartan</a>, or <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>. Each of these agents has limited evidence of efficacy, with few direct comparisons. The choice of one agent over another depends largely on the side effect profile and whether there are additional benefits for other comorbidities. (See <a class="local">'Unable to tolerate or receive preferred initial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent management</strong> – For patients who do not respond adequately to a CCB alone, we typically add or substitute either a PDE5 inhibitor or a topical nitrate The combination of PDE5 inhibitors and topical nitrates should be avoided due to the increased risk of hypotension. In patients who cannot tolerate either of these agents, we use <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> (See <a class="local">'Combination of calcium channel blocker with another agent'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring response to therapy</strong> – Patients should be evaluated periodically, ideally every three to six months, for the need for a particular intervention. It is important to take into account the risk of the intervention, the clinical evidence for its effectiveness, and the need for continued therapy at the time of the evaluation, balancing the risks of therapy and the level of severity of the RP. (See <a class="local">'Monitoring response to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapies lacking efficacy or of uncertain benefit</strong> – A variety of other treatments have been proposed and have been subjected to limited study, and sufficient evidence is lacking at present to support the routine use of any of these therapies. Some examples include behavioral therapy, complementary and alternative medicine, angiotensin converting enzyme (ACE) inhibitors, and <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">prazosin</a>. (See <a class="local">'Therapies lacking efficacy or of uncertain benefit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Primary RP is a benign condition; it is often transient in nature and may improve or disappear with time in one-third or more of patients over 7 to 14 years of follow-up. By comparison, patients with secondary RP are more likely to have severe attacks and sustained or progressive disease. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46:2410.</a></li><li><a class="nounderline abstract_t">Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007; 9:151.</a></li><li><a class="nounderline abstract_t">Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis 2010; 69:588.</a></li><li><a class="nounderline abstract_t">Pauling JD, Frech TM, Hughes M, et al. Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. J Scleroderma Relat Disord 2018; 3:249.</a></li><li><a class="nounderline abstract_t">Gladue H, Maranian P, Paulus HE, Khanna D. Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials. Arthritis Care Res (Hoboken) 2013; 65:630.</a></li><li><a class="nounderline abstract_t">Glenn JK, Goldman J. Task delegation to physician extenders--some comparisons. Am J Public Health 1976; 66:64.</a></li><li><a class="nounderline abstract_t">Pauling JD, Yu L, Frech TM, et al. Construct validity and reliability of the assessment of systemic sclerosis-associated raynaud's phenomenon (ASRAP) questionnaire. Rheumatology (Oxford) 2023.</a></li><li><a class="nounderline abstract_t">Wise RA, Malamet R, Wigley FM. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial. J Rheumatol 1987; 14:278.</a></li><li><a class="nounderline abstract_t">Sandqvist G, Wollmer P, Scheja A, et al. Raynaud's phenomenon and its impact on activities in daily life during one year of follow-up in early systemic sclerosis. Scand J Rheumatol 2018; 47:206.</a></li><li><a class="nounderline abstract_t">Goodfield MJ, Rowell NR. Hand warming as a treatment for Raynaud's phenomenon in systemic sclerosis. Br J Dermatol 1988; 119:643.</a></li><li><a class="nounderline abstract_t">Goodfield MJ, Hume A, Rowell NR. The effect of simple warming procedures on finger blood flow in systemic sclerosis. Br J Dermatol 1988; 118:661.</a></li><li><a class="nounderline abstract_t">Ko GD, Berbrayer D. Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev 2002; 7:328.</a></li><li><a class="nounderline abstract_t">Curtiss P, Cobos G, Lo Sicco K, Franks AG Jr. The Frisbee maneuver: A novel method to abort acute attacks of the Raynaud phenomenon. J Am Acad Dermatol 2018; 78:e61.</a></li><li><a class="nounderline abstract_t">Falkiner S. Diagnosis and treatment of hand-arm vibration syndrome and its relationship to carpal tunnel syndrome. Aust Fam Physician 2003; 32:530.</a></li><li><a class="nounderline abstract_t">Umemura T, Ueda K, Nishioka K, et al. Effects of acute administration of caffeine on vascular function. Am J Cardiol 2006; 98:1538.</a></li><li><a class="nounderline abstract_t">Echeverri D, Montes FR, Cabrera M, et al. Caffeine's Vascular Mechanisms of Action. Int J Vasc Med 2010; 2010:834060.</a></li><li><a class="nounderline abstract_t">O'Keefe JH, Bhatti SK, Patil HR, et al. Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality. J Am Coll Cardiol 2013; 62:1043.</a></li><li><a class="nounderline abstract_t">Freedman RR, Ianni P. Role of cold and emotional stress in Raynaud's disease and scleroderma. Br Med J (Clin Res Ed) 1983; 287:1499.</a></li><li><a class="nounderline abstract_t">Freedman RR, Ianni P. Effects of general and thematically relevant stressors in Raynaud's disease. J Psychosom Res 1985; 29:275.</a></li><li><a class="nounderline abstract_t">Brown KM, Middaugh SJ, Haythornthwaite JA, Bielory L. The effects of stress, anxiety, and outdoor temperature on the frequency and severity of Raynaud's attacks: the Raynaud's Treatment Study. J Behav Med 2001; 24:137.</a></li><li><a class="nounderline abstract_t">Daniels J, Pauling JD, Eccleston C. Behaviour change interventions for the management of Raynaud's phenomenon: a systematic literature review. BMJ Open 2018; 8:e024528.</a></li><li><a class="nounderline abstract_t">Goldman W, Seltzer R, Reuman P. Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: a retrospective case-control study of rheumatology patients. Arthritis Rheum 2008; 58:563.</a></li><li><a class="nounderline abstract_t">Fraenkel L, Zhang Y, Chaisson CE, et al. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 1998; 129:208.</a></li><li><a class="nounderline abstract_t">Evans RW. Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists. Headache 2019; 59:1360.</a></li><li><a class="nounderline abstract_t">Bedrin K, Ailani J, Dougherty C. Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report. Headache 2022; 62:1419.</a></li><li><a class="nounderline abstract_t">Gérard AO, Merino D, Van Obberghen EK, et al. Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. J Headache Pain 2022; 23:53.</a></li><li><a class="nounderline abstract_t">Breen ID, Brumfiel CM, Patel MH, et al. Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon. JAMA Netw Open 2021; 4:e217934.</a></li><li><a class="nounderline abstract_t">Goodfield MJ, Hume A, Rowell NR. The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon. Br J Rheumatol 1990; 29:89.</a></li><li><a class="nounderline abstract_t">Sørensen LT. Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review. Ann Surg 2012; 255:1069.</a></li><li><a class="nounderline abstract_t">Hudson M, Lo E, Lu Y, et al. Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum 2011; 63:230.</a></li><li><a class="nounderline abstract_t">Su KY, Sharma M, Kim HJ, et al. Vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2021; 5:CD006687.</a></li><li><a class="nounderline abstract_t">Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000; 160:1101.</a></li><li><a class="nounderline abstract_t">Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med 1983; 308:880.</a></li><li><a class="nounderline abstract_t">Smith CD, McKendry RJ. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet 1982; 2:1299.</a></li><li><a class="nounderline abstract_t">Sauza J, Kraus A, González-Amaro R, Alarcón-Segovia D. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial. J Rheumatol 1984; 11:362.</a></li><li><a class="nounderline abstract_t">Sarkozi J, Bookman AA, Mahon W, et al. Nifedipine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol 1986; 13:331.</a></li><li><a class="nounderline abstract_t">Kallenberg CG, Wouda AA, Kuitert JJ, et al. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects. J Rheumatol 1987; 14:284.</a></li><li><a class="nounderline abstract_t">Gjørup T, Hartling OJ, Kelbaek H, Nielsen SL. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon. Eur J Clin Pharmacol 1986; 31:387.</a></li><li><a class="nounderline abstract_t">Leppert J, Jonasson T, Nilsson H, Ringqvist I. The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study. Cardiovasc Drugs Ther 1989; 3:397.</a></li><li><a class="nounderline abstract_t">La Civita L, Pitaro N, Rossi M, et al. Amlodipine in the treatment of Raynaud's phenomenon. Br J Rheumatol 1993; 32:524.</a></li><li><a class="nounderline abstract_t">Kallenberg CG, Wouda AA, Meems L, Wesseling H. Once daily felodipine in patients with primary Raynaud's phenomenon. Eur J Clin Pharmacol 1991; 40:313.</a></li><li><a class="nounderline abstract_t">Kinney EL, Nicholas GG, Gallo J, et al. The treatment of severe Raynaud's phenomenon with verapamil. J Clin Pharmacol 1982; 22:74.</a></li><li><a class="nounderline abstract_t">Wigley FM, Wise RA, Malamet R, Scott TE. Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm. Arthritis Rheum 1987; 30:281.</a></li><li><a class="nounderline abstract_t">Kahan A, Amor B, Menkès CJ, et al. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial. Angiology 1987; 38:333.</a></li><li><a class="nounderline abstract_t">Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol 2007; 19:611.</a></li><li><a class="nounderline abstract_t">Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44:1841.</a></li><li><a class="nounderline abstract_t">Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 2005; 44:145.</a></li><li><a class="nounderline abstract_t">Huisstede BM, Hoogvliet P, Paulis WD, et al. Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review. Arch Phys Med Rehabil 2011; 92:1166.</a></li><li><a class="nounderline abstract_t">Ennis H, Hughes M, Anderson ME, et al. Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2016; 2:CD002069.</a></li><li><a class="nounderline abstract_t">Rirash F, Tingey PC, Harding SE, et al. Calcium channel blockers for primary and secondary Raynaud's phenomenon. Cochrane Database Syst Rev 2017; 12:CD000467.</a></li><li><a class="nounderline abstract_t">Kahan A, Weber S, Amor B, et al. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases. Int Angiol 1985; 4:221.</a></li><li><a class="nounderline abstract_t">Khouri C, Lepelley M, Bailly S, et al. Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials. Lancet Rheumatol 2019; 1:e237.</a></li><li><a class="nounderline abstract_t">Maltez N, Maxwell LJ, Rirash F, et al. Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon. Cochrane Database Syst Rev 2023; 11:CD014089.</a></li><li><a class="nounderline abstract_t">Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis 2013; 72:1696.</a></li><li><a class="nounderline abstract_t">Roustit M, Giai J, Gaget O, et al. On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials. Ann Intern Med 2018; 169:694.</a></li><li><a class="nounderline abstract_t">Herrick AL. Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr Opin Rheumatol 2011; 23:555.</a></li><li><a class="nounderline abstract_t">Tucker AT, Pearson RM, Cooke ED, Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial. Lancet 1999; 354:1670.</a></li><li><a class="nounderline abstract_t">Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum 2009; 60:870.</a></li><li><a class="nounderline abstract_t">Kan C, Akimoto S, Abe M, et al. Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis. Ann Rheum Dis 2002; 61:177.</a></li><li><a class="nounderline abstract_t">Teh LS, Manning J, Moore T, et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon. Br J Rheumatol 1995; 34:636.</a></li><li><a class="nounderline abstract_t">Curtiss P, Schwager Z, Cobos G, et al. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon. J Am Acad Dermatol 2018; 78:1110.</a></li><li><a class="nounderline abstract_t">Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42:2646.</a></li><li><a class="nounderline abstract_t">Jaffe IA. Serotonin reuptake inhibitors in Raynaud's phenomenon. Lancet 1995; 345:1378.</a></li><li><a class="nounderline abstract_t">Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001; 40:1038.</a></li><li><a class="nounderline abstract_t">Hughes M, Snapir A, Wilkinson J, et al. Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception. Rheumatology (Oxford) 2015; 54:1443.</a></li><li><a class="nounderline abstract_t">Stjernbrandt A, Wahlström J. The impact of Raynaud's phenomenon on work ability - a longitudinal study. J Occup Med Toxicol 2022; 17:12.</a></li><li><a class="nounderline abstract_t">Hughes M, Khanna D, Pauling JD. Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target? Rheumatology (Oxford) 2020; 59:464.</a></li><li><a class="nounderline abstract_t">Hughes M, Huang S, Pauling JD, et al. The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis. Clin Rheumatol 2022; 41:3049.</a></li><li><a class="nounderline abstract_t">Freedman RR, Ianni P, Wenig P. Behavioral treatment of Raynaud's disease. J Consult Clin Psychol 1983; 51:539.</a></li><li><a class="nounderline abstract_t">Freedman RR, Ianni P, Wenig P. Behavioral treatment of Raynaud's phenomenon in scleroderma. J Behav Med 1984; 7:343.</a></li><li><a class="nounderline abstract_t">Guglielmi RS, Roberts AH, Patterson R. Skin temperature biofeedback for Raynaud's disease: a double-blind study. Biofeedback Self Regul 1982; 7:99.</a></li><li><a class="nounderline abstract_t">Sporbeck B, Mathiske-Schmidt K, Jahr S, et al. Effect of biofeedback and deep oscillation on Raynaud's phenomenon secondary to systemic sclerosis: results of a controlled prospective randomized clinical trial. Rheumatol Int 2012; 32:1469.</a></li><li><a class="nounderline abstract_t">Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford) 2009; 48:791.</a></li><li><a class="nounderline abstract_t">Mariani E, Mangialasche F, Feliziani FT, et al. Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects. Exp Gerontol 2008; 43:445.</a></li><li><a class="nounderline abstract_t">Al-Sheikh YA, Ghneim HK. 'The effect of micronutrients on superoxide dismutase in senescent fibroblasts'. Cell Biochem Funct 2011; 29:384.</a></li><li><a class="nounderline abstract_t">Eby GA, Halcomb WW. High-dose zinc to terminate angina pectoris: a review and hypothesis for action by ICAM inhibition. Med Hypotheses 2006; 66:169.</a></li><li><a class="nounderline abstract_t">Sambo P, Amico D, Giacomelli R, et al. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. J Rheumatol 2001; 28:2257.</a></li><li><a class="nounderline abstract_t">Rosato E, Borghese F, Pisarri S, Salsano F. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol 2009; 28:1379.</a></li><li><a class="nounderline abstract_t">Denton CP, Bunce TD, Dorado MB, et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology (Oxford) 1999; 38:309.</a></li><li><a class="nounderline abstract_t">Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial. Vasc Med 2002; 7:265.</a></li><li><a class="nounderline abstract_t">Bredie SJ, Jong MC. No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial. J Cardiovasc Pharmacol 2012; 59:215.</a></li><li><a class="nounderline abstract_t">Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med 1997; 241:119.</a></li><li><a class="nounderline abstract_t">Hirschl M, Katzenschlager R, Ammer K, et al. Double-blind, randomised, placebo controlled low level laser therapy study in patients with primary Raynaud's phenomenon. Vasa 2002; 31:91.</a></li><li><a class="nounderline abstract_t">Hirschl M, Katzenschlager R, Francesconi C, Kundi M. Low level laser therapy in primary Raynaud's phenomenon--results of a placebo controlled, double blind intervention study. J Rheumatol 2004; 31:2408.</a></li><li><a class="nounderline abstract_t">Neuhauser B, Perkmann R, Klingler PJ, et al. Clinical and objective data on spinal cord stimulation for the treatment of severe Raynaud's phenomenon. Am Surg 2001; 67:1096.</a></li><li><a class="nounderline abstract_t">Tosi S, Marchesoni A, Messina K, et al. Treatment of Raynaud's phenomenon with captopril. Drugs Exp Clin Res 1987; 13:37.</a></li><li><a class="nounderline abstract_t">Gliddon AE, Doré CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007; 56:3837.</a></li><li><a class="nounderline abstract_t">Russell IJ, Lessard JA. Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study. J Rheumatol 1985; 12:94.</a></li><li><a class="nounderline abstract_t">Wollersheim H, Thien T, Fennis J, et al. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. Clin Pharmacol Ther 1986; 40:219.</a></li><li><a class="nounderline abstract_t">Wollersheim H, Thien T. Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects. J Clin Pharmacol 1988; 28:1089.</a></li><li><a class="nounderline abstract_t">LeRoy EC, Downey JA, Cannon PJ. Skin capillary blood flow in scleroderma. J Clin Invest 1971; 50:930.</a></li><li><a class="nounderline abstract_t">Robson P, Pearce V, Antcliff AC, Hamilton M. Double-blind trial of indoramin in digital artery disease. Br J Clin Pharmacol 1978; 6:88.</a></li><li><a class="nounderline abstract_t">Varadi DP, Lawrence AM. Suppression of Raynaud's phenomenon by methyldopa. Arch Intern Med 1969; 124:13.</a></li><li><a class="nounderline abstract_t">Russell IJ, Walsh RA. Selection of vasodilator therapy for severe Raynaud's phenomenon by sequential arterial infusion. Ann Rheum Dis 1985; 44:151.</a></li><li><a class="nounderline abstract_t">Coffman JD, Cohen RA. Intra-arterial vasodilator agents to reverse human finger vasoconstriction. Clin Pharmacol Ther 1987; 41:574.</a></li><li><a class="nounderline abstract_t">Willerson JT, Thompson RH, Hookman P, et al. Reserpine in Raynaud's disease and phenomenon. Short-term response to intra-arterial injection. Ann Intern Med 1970; 72:17.</a></li><li><a class="nounderline abstract_t">McFadyen IJ, Housley E, MacPherson AI. Intraarterial reserpine administration in Raynaud syndrome. Arch Intern Med 1973; 132:526.</a></li><li><a class="nounderline abstract_t">PRANDONI AG, MOSER M. Clinical appraisal of intra-arterial priscoline therapy in the management of peripheral arterial diseases. Circulation 1954; 9:73.</a></li><li><a class="nounderline abstract_t">Wise RA, Wigley FM, White B, et al. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004; 50:3994.</a></li><li><a class="nounderline abstract_t">Neirotti M, Longo F, Molaschi M, et al. Functional vascular disorders: treatment with pentoxifylline. Angiology 1987; 38:575.</a></li><li><a class="nounderline abstract_t">Eid AH, Maiti K, Mitra S, et al. Estrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 2007; 293:H1955.</a></li><li><a class="nounderline abstract_t">Generini S, Seibold JR, Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud's phenomenon. Rheum Dis Clin North Am 2005; 31:177.</a></li><li><a class="nounderline abstract_t">Lekakis J, Papamichael C, Mavrikakis M, et al. Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis. Am J Cardiol 1998; 82:1555.</a></li><li><a class="nounderline abstract_t">Coffman JD, Clement DL, Creager MA, et al. International study of ketanserin in Raynaud's phenomenon. Am J Med 1989; 87:264.</a></li><li><a class="nounderline abstract_t">Khan F, Litchfield SJ, McLaren M, et al. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. Arthritis Rheum 1997; 40:352.</a></li><li><a class="nounderline abstract_t">Bunker CB, Reavley C, O'Shaughnessy DJ, Dowd PM. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. Lancet 1993; 342:80.</a></li><li><a class="nounderline abstract_t">Ettinger WH, Wise RA, Schaffhauser D, Wigley FM. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. Am J Med 1984; 77:451.</a></li><li><a class="nounderline abstract_t">Bowling JC, Dowd PM. Raynaud's disease. Lancet 2003; 361:2078.</a></li><li><a class="nounderline abstract_t">Kumagai S, Morinobu A, Ozaki S, et al. [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases]. Ryumachi 1998; 38:504.</a></li><li><a class="nounderline abstract_t">Kato S, Kishiro I, Ohnuma N, et al. Suppressive effect of saprogrelate hydrochloride on Raynaud's phenomenon and respiratory failure in patients with systemic sclerosis. Respirology 2000; 5:27.</a></li><li><a class="nounderline abstract_t">Yoshimasu T, Ikeda T, Uede K, et al. Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis. J Dermatol 2012; 39:536.</a></li><li><a class="nounderline abstract_t">Zhang J, Hu J, He X, et al. Effectiveness of Chinese herbal medicine for primary Raynaud's phenomenon: a systematic review and Meta-analysis of randomized controlled trials. J Tradit Chin Med 2020; 40:509.</a></li><li><a class="nounderline abstract_t">Carpentier PH, Satger B, Poensin D, Maricq HR. Incidence and natural history of Raynaud phenomenon: A long-term follow-up (14 years) of a random sample from the general population. J Vasc Surg 2006; 44:1023.</a></li><li><a class="nounderline abstract_t">Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 2005; 52:1259.</a></li><li><a class="nounderline abstract_t">Murphy SL, Lescoat A, Alore M, et al. How do patients define Raynaud's phenomenon? Differences between primary and secondary disease. Clin Rheumatol 2021; 40:1611.</a></li></ol></div><div id="topicVersionRevision">Topic 7540 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12355489" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502046" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Outcome measures in systemic sclerosis: an update on instruments and current research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19364728" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30705970" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972592" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Task delegation to physician extenders--some comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37481713" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Construct validity and reliability of the assessment of systemic sclerosis-associated raynaud's phenomenon (ASRAP) questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3298649" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28803485" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Raynaud's phenomenon and its impact on activities in daily life during one year of follow-up in early systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3207617" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hand warming as a treatment for Raynaud's phenomenon in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2969257" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effect of simple warming procedures on finger blood flow in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12197784" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of ceramic-impregnated "thermoflow" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29017842" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Frisbee maneuver: A novel method to abort acute attacks of the Raynaud phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12901208" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnosis and treatment of hand-arm vibration syndrome and its relationship to carpal tunnel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17126666" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effects of acute administration of caffeine on vascular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21188209" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Caffeine's Vascular Mechanisms of Action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23871889" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6416474" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Role of cold and emotional stress in Raynaud's disease and scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4032326" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effects of general and thematically relevant stressors in Raynaud's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11392916" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The effects of stress, anxiety, and outdoor temperature on the frequency and severity of Raynaud's attacks: the Raynaud's Treatment Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30552281" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Behaviour change interventions for the management of Raynaud's phenomenon: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18240233" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: a retrospective case-control study of rheumatology patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9696729" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31310337" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36426766" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35505285" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33871613" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2182173" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22566015" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20936633" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cigarette smoking in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33998674" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Vasodilators for primary Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10789602" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6339921" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6128596" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6376801" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3723496" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nifedipine in the treatment of idiopathic Raynaud's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3598997" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3816916" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2535054" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8508292" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Amlodipine in the treatment of Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2060571" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Once daily felodipine in patients with primary Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7037872" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The treatment of severe Raynaud's phenomenon with verapamil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2952125" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3555175" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17917543" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11508437" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15546967" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21704799" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26914257" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Calcium channel blockers for primary Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29237099" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Calcium channel blockers for primary and secondary Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3831143" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38229380" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37929840" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23426043" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383134" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21885977" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Contemporary management of Raynaud's phenomenon and digital ischaemic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10568568" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19248104" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796408" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Preliminary thermographic evaluation of new nitroglycerine tape on the peripheral circulatory disturbance in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7670782" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29408338" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10616013" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7752794" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Serotonin reuptake inhibitors in Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561116" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25752312" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35676726" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The impact of Raynaud's phenomenon on work ability - a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31670800" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35583625" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6619361" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Behavioral treatment of Raynaud's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6520866" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Behavioral treatment of Raynaud's phenomenon in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7093357" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Skin temperature biofeedback for Raynaud's disease: a double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21476099" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Effect of biofeedback and deep oscillation on Raynaud's phenomenon secondary to systemic sclerosis: results of a controlled prospective randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19433434" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18078731" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21538411" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : 'The effect of micronutrients on superoxide dismutase in senescent fibroblasts'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16084666" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : High-dose zinc to terminate angina pectoris: a review and hypothesis for action by ICAM inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11669166" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19690939" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10378706" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12710841" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22030896" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : No significant effect of ginkgo biloba special extract EGb 761 in the treatment of primary Raynaud phenomenon: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9077368" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12099151" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Double-blind, randomised, placebo controlled low level laser therapy study in patients with primary Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15570642" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Low level laser therapy in primary Raynaud's phenomenon--results of a placebo controlled, double blind intervention study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11730228" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Clinical and objective data on spinal cord stimulation for the treatment of severe Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3297593" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Treatment of Raynaud's phenomenon with captopril.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17968938" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3884807" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3731684" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3243924" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5547282" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Skin capillary blood flow in scleroderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/352379" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Double-blind trial of indoramin in digital artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5791479" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Suppression of Raynaud's phenomenon by methyldopa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3977418" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Selection of vasodilator therapy for severe Raynaud's phenomenon by sequential arterial infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3105944" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Intra-arterial vasodilator agents to reverse human finger vasoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5410395" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Reserpine in Raynaud's disease and phenomenon. Short-term response to intra-arterial injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4742406" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Intraarterial reserpine administration in Raynaud syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13116379" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Clinical appraisal of intra-arterial priscoline therapy in the management of peripheral arterial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15593189" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3631642" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Functional vascular disorders: treatment with pentoxifylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17644575" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Estrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15639062" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Estrogens and neuropeptides in Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9874070" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Effect of long-term estrogen therapy on brachial arterial endothelium-dependent vasodilation in women with Raynaud's phenomenon secondary to systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2672807" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : International study of ketanserin in Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041947" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8100913" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6540986" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814733" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Raynaud's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9721558" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10728728" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Suppressive effect of saprogrelate hydrochloride on Raynaud's phenomenon and respiratory failure in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22077618" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32744019" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Effectiveness of Chinese herbal medicine for primary Raynaud's phenomenon: a systematic review and Meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17098538" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Incidence and natural history of Raynaud phenomenon: A long-term follow-up (14 years) of a random sample from the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15818710" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The incidence and natural history of Raynaud's phenomenon in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33486597" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : How do patients define Raynaud's phenomenon? Differences between primary and secondary disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
